Total trials
66
Active
13
Phase 3
10
Total enrollment
8,100
Pipeline matrix
Showing 25 of 25 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| TAS6417 | — | — | — | — | 3 | ||
| Futibatinib | — | — | — | — | 7 | ||
| Cisplatin | — | — | — | — | 4 | ||
| Venetoclax | — | — | — | — | 2 | ||
| Carboplatin | — | — | — | — | — | 1 | |
| Pemetrexed | — | — | — | — | — | 1 | |
| Zipalertinib Matching-placebo | — | — | — | — | — | 1 | |
| Azacitidine | — | — | — | — | — | 1 | |
| ASTX030 | — | — | — | — | — | 1 | |
| Cedazuridine | — | — | — | — | — | 1 | |
| futibatinib, fulvestrant | — | — | — | — | — | 1 | |
| ASTX727 | — | — | — | — | 3 | ||
| Pembrolizumab | — | — | — | — | — | 2 | |
| ASTX660 | — | — | — | — | — | 1 | |
| CYP Cocktail | — | — | — | — | — | 1 | |
| Transporter Cocktail | — | — | — | — | — | 1 | |
| Decitabine and Cedazuridine | — | — | — | — | — | 1 | |
| 5-FU | — | — | — | — | — | 1 | |
| Oxaliplatin | — | — | — | — | — | 1 | |
| Leucovorin | — | — | — | — | — | 1 | |
| Levoleucovorin | — | — | — | — | — | 1 | |
| Irinotecan | — | — | — | — | — | 1 | |
| TAS-120 | — | — | — | — | 2 | ||
| ARC-02 | — | — | — | — | — | 1 | |
| Rituximab | — | — | — | — | — | 1 |
Next readouts
- 2022-10
- 2024-09-30
- 2026-01-28
- 2026-10-29
- 2026-12
- 2026-12
- 2026-12
- 2027-04
- 2027-11-01
- 2027-12-31
Top conditions
- Advanced Solid Tumors8
- Acute Myeloid Leukemia6
- Myelodysplastic Syndromes5
- Advanced Cholangiocarcinoma3
- Gastric Cancer3
- Non-Small Cell Lung Cancer3
- Advanced Non-Small Cell Lung Cancer2
- Advanced Hepatocellular Carcinoma2
Frequently asked questions about Taiho Oncology, Inc.
- How many clinical trials does Taiho Oncology, Inc. have on ClinicalTrials.gov?
- Taiho Oncology, Inc. is listed as the lead sponsor on 66 clinical trials in ClinicalTrials.gov, 13 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Taiho Oncology, Inc.'s trials are in Phase 3?
- 10 of Taiho Oncology, Inc.'s trials are in Phase 3, spread across 25 active drug programs.
- What therapeutic areas does Taiho Oncology, Inc. focus on?
- Taiho Oncology, Inc.'s most-studied conditions on ClinicalTrials.gov are Advanced Solid Tumors, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Advanced Cholangiocarcinoma, Gastric Cancer.
- When are Taiho Oncology, Inc.'s next clinical trial readouts?
- Taiho Oncology, Inc. has 10 upcoming primary-completion readouts tracked here; the soonest is “Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas”, expected around 2022-10.